Animal Testing
Animals are traditionally used as test subjects during drug development studies in order to reliably detect the toxic properties of chemicals. The purpose of animal testing is to study and try and predict how chemical substances might interact and affect normal biological functions in humans.
Therapeutic Value
Drug companies are better able to predict safe drug exposure levels that offer therapeutic value and enhance the preservation of human health by testing the effects that certain chemicals have on animals. Toxicology testing is a highly important and crucial part of any drug study, helping patients to live safely and derive the intended benefits of natural and synthetic substances while avoiding harm.
Toxicology Testing
Eliminating the use of animals in toxicology testing, is a difficult challenge. The purpose of this paper is to discuss the evolving methods to test toxicology in ways that minimize the negative impact on animals as much as possible.
Toxicity Testing in Animals
The pharmaceutical world is constantly evolving and companies around the world have a desire to reduce animal use in toxicology testing. The introduction of small laboratory animal research almost a hundred years ago brought security to the regulated community and allowed international harmonization regarding toxicity standards for human usage (Hartung and Leist, 2005 pg.91).
Animal Research
For many years toxicology has been frozen in time, however the replacement, refinement, and reduction of animals in research (the 3R’s) is a well-established concept, originally described in 1959. Throughout the 1960s and 1970s this idea of alternatives to animal research increased visibility, and finally gained momentum in the 1980s when governments, academia, and industry became more involved (Chapman et, al. 2013, p.89) with this initiative. It has only been 50 years since the initial publication that the 3R’s are truly coming to age, with growing recognition of their benefits and widespread efforts to identify new opportunities for implementation (Chapman et, al. 2013, pg.89).
NHGRI
Additionally, there are many organizations and research groups working to evolve this historic process: Francis Collin, Director of the National Human Genome Research Institute states “[toxicity testing] was expensive, time-consuming, used animals in large numbers and didn’t always work” (Hartung and Leist, 2005 pg.91).
Drug Development
An international workshop was convened to identify opportunities to further reduce animal use and improve efficiency in drug development (Chapman et, al. 2013, p.89). An important driver for new development and reproductive toxicity guidelines established by the International Conference on Harmonization (ICH) was to produce guidelines that used fewer animals while still providing adequate evaluation of the exposure to a chemical at any point (Chapman et al, 2013. p.93).
Regulatory Studies
Today, the industry is observing more and more disconnect between the development of a mechanistic, modern toxicology program and the rigid approaches governing the regulatory requirements (Hartung and Leist, 2005 pg.91). The discovery of new information rich pathways and technologies, combined with scientific knowledge can be used to minimize the use of animals in regulatory studies and overall drug development.
3R’s
The Replacement, Refinement and Reduction (3R’s) concept acts as the foundation of the methods and approaches mentioned below. These methods do not fully remove animal use in regulatory studies, instead they suggest ways of implementing practices in toxicology testing that attempt to minimize studies that require animal use.
Data Analysis
It is important to recognize that even though these methods drive development of more efficient and less animal-dependent tools for safety testing, data derived from novel testing may not be accepted for traditional regulatory industry standards that exist today (Hartung and Leist, 2005 pg.94). Company will need to fully research each method and the correct data analysis procedure. Given their importance, the utility of animal models for prediction of human safety should be regularly reviewed as advances in both scientific understanding and technical methods continue to evolve (Chapman et, al. 2013 p.88).
Method Overview
The international workshop convened to identify opportunities to reduce animal use and improve efficiency in drug development. Various related themes included (1) accelerating the progress and uptake of in vitro methods, (2) incorporating that latest science into safety pharmacology assessments, (3) optimizing designs for rodent studies to support the development of biologicals, and (4) consolidating various approaches and endpoints in developmental and reproduction (Chapman et al, 2013. p.89).
The methods described below can be used to help reduce animal use in regulatory studies:
I. Development of New Vitro Approaches
The development of new in-vitro approaches to replace animal bioassay testing for assessing potential human toxicity of compounds in drug development has the potential to greatly reduce the need for animal testing. The following models discuss the multiple drivers for developing new in vitro approaches including scientific and technology advances, and legislative changes. (Chapman et, al. 2013, p.89)
a. Mechanism-based Models
There is a challenge regarding the lack regulatory acceptance of in vitro methods. According to Chapman, there are two general classes of biological methods used in the discovery and development of new products: holistic bioassays and methods that evaluate specific biological mechanisms eg. in vitro and in vivo. The regulatory validation process of in vitro methods to replace an in vivo bioassay may deter scientists from developing them because it can be difficult to design an in-vitro test that adequately mimics the performance of the drug when using an in-vivo method.
However, not all scientifically validated methodologies require regulatory acceptance. By focusing on intended use the scientific validation becomes significantly less intimidating. (Chapman et al. 2013. p.90).
b. Predicative Toxicology
Currently, the high failure rate of candidate drugs after the decision to begin regulatory toxicology testing represents the largest opportunity to reduce overall animal use. (Chapman et, al. 2013, p.90). According to Chapman, “nine out of ten candidates beginning clinical phase I will not achieve marketing approval. However, much of regulatory animal testing is front-loaded and must be completed before clinical trials may proceed. Therefore, as candidates fail in clinical development, the animal testing associated with those failures could have been avoided” (Chapman et, al. 2013 p.91).
The use of predictive in vitro techniques will attribute to better decisions in the drug design which will lead to: improvement of the quality of candidate drugs, decrease drug candidate attrition rates due to toxicology incompatibility, and ultimately reduce the number of animals used (Chapman et, al. 2013, p.91). OECD Test Guideline no.404 recommends the conduct of the in vitro assays to limit the severity of toxicity for compounds that progress to in vivo evaluation (Chapman et, al. 2013 p.91).
Also, it is important to note, in vitro studies can be used to improve the predictive value of in vivo toxicology studies by supporting the selection of appropriate animal species by ensuring that testing is not conducted in species that lack human relevance (Chapman et, al. 2013 p.91).
II. Ensuring Appropriate Statistical Analysis
This section provides opportunities to improve efficiency in safety pharmacology studies by ensuring appropriate statistical analysis and science are incorporated into your practices.
a. Combining Studies
This approach is common among biologics and anti-cancer therapeutics however many drug companies shy away from the combination of toxicology studies because of the fear of regulatory disapproval. According to Chapman, “animal use may be reduced by replacing standalone safety pharmacology studies with integrated toxicology studies, which is consistent with the ICH guidance.
When studies are combined, animal use may be reduced by 20-40%” (Chapman et, al. 2013, p.92). Incorporating safety endpoints into toxicology studies that are being carried out at an IND stage, can be applicable to the Clinical Trial Application. Though this approach is less common, it has a great potential to reduce animal use and is gaining strength among regulators;
The Safety Pharmacology Society released a “Best Practices” document which contains recommendations to reduce potential further animal use to improve experimental accuracy (Chapman et, al 2013, p.92)
b. Improve Data
Investigators sometimes fail to incorporate measurement error and statistical power into study designs and interpretation, which leads to repeat experiments. According to the OECD TG 425, “information that will help in the focus of the study design on the test substance includes, the identity, chemical structure, and physic-chemical properties of the test substance, this will allow you to more efficiently test for chronic toxicity potential and minimize animal usage” (OECD, 2008 p.2).
Likewise, increasing animal use is not necessary to increase statistical power (Chapman et, al 2013. P.92). “By employing more sensitive measurement techniques, such as chronic or jacketed telemetry raw measurement error can be reduced” (Chapman et, al 2013 p.92). This improvement in statistical power reduces the number of observations necessary to establish given data. (Chapman et, al. 2013 p.92).
III. Making Dart Testing More Efficient
The ICH S5 guidance on testing the medicines for reproductive toxicity was the first harmonized guideline for nonclinical testing to half the numbers of animals required for evaluating Development and Reproductive Toxicology (DART) hazard of new drugs. (Chapman et, al 2013 p.93).
a. Use of DRF Data
According to Chapman, it may be possible to make decisions early in drug development that could prevent the need for a full embryo fetal development (EFD) test in two species. The ICH S5 guidance recommends the appropriate numbers of animals should be used, therefore usually the does range finding (DRF) is found prior to the EFD test; If a positive result with clear evidence from development toxicity is found in the DRF EFD study then it is unlikely another study will provide additional data for safety and labeling (Chapman et al, 2013 p.94).
The toxicity level of the new chemical may be a risk when considering this model, however alternative development toxicity assays are being studied and are promising to provide valuable information in predicting human hazard. (Chapman et, al 2013 p.94).
b. Rodent Models for Safety Assessment
It is evident that animal use cannot completely be eliminated, however the OCED TG 452 gives recommendation to ways to optimize animal testing in rodents. In this guideline the preferred rodent species is the rat, although other rodent species, eg, the mouse may be used.
Rats and mice have been preferred experimental models because of their relatively short life span, their widespread use in pharmacological and toxicological studies, their susceptibility to tumor induction, a large amount of information is available on their physiology ad pathology (OCED, 2008 p.2).
Recommendation
The purpose of these methods is to discuss the processes for regulatory acceptances of alternatives in animal toxicology testing, including the need for formal validation studies on some occasions but proof of scientific validity on others. (Chapman et al, 2013 p.89). Many of these alternatives can will be tailored to a particular program and development needs.
However, it is recommended that companies focus on studies that directly impact and guide future research directions, so overall reductions in animal use would be maximized. The need for a leader in the industry in protecting animal welfare is high. Global commitment of companies, academic organizations, and regulators is needed to take 3R’s out of the competitive arena and to commit to share all they know and learn, for the benefit of the animals.
There are many unrealized benefits and incentives that may be realized by employing a scientific approach to review and refine animal use. (Chapman et, al. 2013, p.101).
About RCA’s Pharmaceutical Consulting Services
Regulatory Compliance Associates (RCA) has helped thousands of pharmaceutical companies meet regulatory, compliance, quality assurance, and remediation challenges. With more than 20 years of experience with FDA, Health Canada, EU and global regulatory agencies worldwide, Regulatory Compliance Associates® offers leading pharmaceutical consultants. We’re one of the few pharma consulting companies that can help you navigate the challenges associated with industry regulations.
Our pharmaceutical consulting firm includes over 500 seasoned FDA, Health Canada & EU compliance consultants and regulatory affairs experts who understand industry complexities. It’s a pharma consultancy founded by regulatory compliance executives from the pharmaceutical industry. Every pharmaceutical industry consultant on the Regulatory Compliance Associates team knows the unique inner workings of the regulatory process.
Client Solutions
Whether you’re in the product planning, development or pharmaceutical lifecycle management stage or need a remediation strategy for a compliance crisis, Regulatory Compliance Associates will guide you through every pharmaceutical consulting step of the regulatory process and create a customized approach depending on your product and your pharma company’s individual needs. Our regulatory compliance clients include:
- Companies new to FDA, Health Canada or EU regulations and regulatory compliance
- Start-up organizations with novel submissions to 510(k) submissions from multi-national corporations
- Investment firms seeking private equity due diligence for pre-acquisition and post-deal research
- Law firms seeking pharmaceutical consulting firm expertise in the remediation of warning letters, consent decrees, 483’s or import bans
Regulatory Affairs
Regulatory affairs is Regulatory Compliance Associates backbone. We exceed other pharma consulting companies with industry experts experienced in complexities of the pharmaceutical and biopharmaceutical industries. Our pharma consulting expertise spans all facets and levels of Regulatory Affairs, from Regulatory Support for New Products to Life Cycle Management, to other services like Outsourced Regulatory Affairs, Submissions, Training, and more.
As your partner, we can negotiate the potential assessment minefield of regulatory compliance services with insight, hindsight, and the clear advantage of our breadth and depth of knowledge and regulatory compliance consulting. We offer the following pharma consulting regulatory affairs services for pharmaceutical companies.
- New Product Support
- Product Lifecycle
- Other Regulatory Services
- Combination Products
Compliance Assurance
The regulations process surrounding pharmaceutical companies can be tricky for even the most experienced industry veteran to understand. Just one misstep could mean significant and lasting consequences for your business. At Regulatory Compliance Associates, we offer the pharma consulting experience and pharma consultants necessary to guide you through the quality compliance process.
- Assessments
- Audits
- Regulatory Agency Response
- Preparation and Training
- Inspection Readiness
- Data Integrity
Quality Assurance
Regulatory Compliance Associates Quality consulting includes assessments, strategy, implementations, staff augmentations, and identification of quality metrics to ensure continuous improvement. Our pharma consultants understand the strategic thinking needed to align your business needs and goals. Regulatory Compliance Associates quality assurance services include quality experts with experience spanning major corporations and start-ups. Our pharmaceutical consulting firm knows firsthand how to achieve, maintain, and improve quality, and we excel in transferring pharma consulting knowledge to your organization.
- 21 CFR Part 11
- Data Integrity
- Manufacturing Support
- Facility Support
- Quality Metrics
Remediation Services
Regulatory Compliance Associates has a proven remediation services approach to managing FDA Warning Letters, Consent Decrees, Remediation and other serious regulatory situations. Our pharma consultants know how to partner with executive, legal, and communication teams. Each RCA pharma consulting Expert will develop a response that will be accepted by the regulatory agency and be realistic to execute.
Regulatory Compliance Associates pharma regulatory consultants will develop a comprehensive proof book of documented evidence demonstrating the corrective action taken to remediate non-compliant issues. In addition, each Regulatory Compliance Associates pharma consulting Expert understands compliance enforcement. We’ll prepare a comprehensive pharma consulting strategy to assist in your remediation efforts, drive continuous improvement, and maintain regulatory compliance with the regulations.
- Regulatory Action
- Regulatory Compliance
- Regulatory Enforcement
- Warning Letter
- 483 Observation
- Oversight Services
- Risk Management Plan
About Regulatory Compliance Associates
Regulatory Compliance Associates® (RCA) provides pharmaceutical consulting to the following industries for resolution of life science challenges:
- Life Sciences
- Pharmaceutical
- Biologic & Biotechnology
- Sterile compounding
- Medical device
- Lab Testing
We understand the complexities of running a life science business and possess areas of expertise that include every facet of R&D, operations, regulatory affairs, quality, and manufacturing. We are used to working on the front lines and thriving in the scrutiny of FDA, Health Canada, MHRA and globally-regulated companies.
As your partners, we can negotiate the potential minefield of regulatory compliance and regulatory due diligence with insight, hindsight, and the clear advantage of our unique expertise and experience.
- Founded in 2000
- Headquartered in Wisconsin (USA)
- Expertise backed by over 500 industry subject matter experts
- Acquired by Sotera Health in 2021
About Sotera Health
The name Sotera Health was inspired by Soteria, the Greek goddess of safety, and reflects the Company’s unwavering commitment to its mission, Safeguarding Global Health®.
Sotera Health Company, along with its three best-in-class businesses – Sterigenics®, Nordion® and Nelson Labs®, is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. With a combined tenure across our businesses of nearly 200 years and our industry-recognized scientific and technological expertise, we help to ensure the safety of over 190 million patients and healthcare practitioners around the world every year.
We are a trusted partner to 5,800+ customers in over 50 countries, including 40 of the top 50 medical device companies and 9 of the top 10 pharmaceutical companies.
Commitment to Quality
Our Certificate of Registration demonstrates that our Quality Management System meets the requirements of ISO 9001:2015, an internationally recognized standard of quality.
To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage.
Resources
1. Authors: Chapman, Kathryn L, Holzgrefe Henry., Black, Lauren E., Brown, Marilyn, Chellman, Gary, Copeman, Christine. . . .Wilson, Stephen. (2013) Regulatory Toxicology and Pharmacology. Journal of Elsevier Inc, 66, 88-103.
2. Hartung, T. & Leist, Marcel (2008). Food for Thought… on the Evolution of Toxicology and the Phasing out of Animal Testing. Altex; 25, (91-96).
3. OECG TG 452 (2008)
4. Test Guideline 452: Chronic Toxicity Studies